Vitreal penetration of oral and topical moxifloxacin in humans.

Academic Article


  • PURPOSE: To investigate the vitreal penetration of moxifloxacin after oral and topical administration. DESIGN: Prospective, nonrandomized clinical trial. METHODS: Twenty-four patients were assigned to one of four dosing groups: control (n = 3), which received no medication; oral (n = 8), which received two 400 mg oral doses of moxifloxacin before surgery; topical (n = 8), which received one drop of topical moxifloxacin 0.5% every 15 minutes for the hour preceding surgery; and combined (n = 5), which received two 400 mg oral doses and one drop of topical moxifloxacin 0.5% hourly for 18 hours prior to surgery. Vitreous samples were obtained and analyzed. RESULTS: Control, below quantifiable levels; oral, 1.553 +/- 0.33 microg/ml; topical, 0.027 microg/ml; and combined, 2.219 +/- 0.71 microg/ml. One topical patient developed postoperative endophthalmitis. CONCLUSIONS: In contrast to topical moxifloxacin, oral moxifloxacin achieves significant levels in the noninflamed human vitreous.
  • Authors

    Published In


  • Administration, Oral, Administration, Topical, Adult, Aged, Aged, 80 and over, Anti-Infective Agents, Aza Compounds, Biological Availability, Chromatography, High Pressure Liquid, Female, Fluoroquinolones, Humans, Male, Middle Aged, Moxifloxacin, Prospective Studies, Quinolines, Vitrectomy, Vitreous Body
  • Digital Object Identifier (doi)

    Author List

  • Fuller JJ; Lott MN; Henson NM; Bhatti AA; Singh H; McGwin G; Marcus DM
  • Start Page

  • 338
  • End Page

  • 340
  • Volume

  • 143
  • Issue

  • 2